Global CRO footprint Clinipace Worldwide (formerly Choice Pharma) operates as a global digital CRO with offices worldwide and a track record of supporting over 3,000 clinical studies and more than 300 regulatory and development projects, indicating a scalable platform for multinational trials and regulatory services.

Integrated eClinical suite Powered by TEMPO™, Clinipace offers an integrated eClinical platform that spans regulatory strategy, clinical development, and post-approval research, presenting a unified service proposition to sponsors seeking end-to-end trial management.

Therapeutic breadth Deep therapeutic expertise across cardiovascular, CNS, dermatology, GI, immunology, infectious diseases, oncology, vaccines, and more positions Clinipace to cross-sell into multiple indications, appealing to sponsors with diversified portfolios.

M&A and leadership momentum Historical mergers (Accovion 2015, Choice Pharma 2014) and leadership additions (COO appointment, regulatory and analytics leadership) suggest a growth-oriented roadmap with integration traction that can be leveraged to pitch expanded capabilities to clients.

Financial and client growth signals Revenue range indicates a mid-sized CRO with growth potential; funding rounds in prior years, combined with expansions and partnerships (e.g., Virgo Llc), imply opportunities to upsell scaling programs, larger studies, and strategic development services.